214 related articles for article (PubMed ID: 37790933)
1. Identification of lactate regulation pattern on tumor immune infiltration, therapy response, and DNA methylation in diffuse large B-cell lymphoma.
Wang J; Wang Y; Wan L; Chen X; Zhang H; Yang S; Zhong L
Front Immunol; 2023; 14():1230017. PubMed ID: 37790933
[TBL] [Abstract][Full Text] [Related]
2. Implication of immune cell signature of tumor microenvironment in diffuse large B-cell lymphoma.
Yu H; Fu D; Xu PP; Cheng S; Wang L; Zhang YZ; Zhao WL
Hematol Oncol; 2021 Dec; 39(5):616-624. PubMed ID: 34331367
[TBL] [Abstract][Full Text] [Related]
3. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
Front Immunol; 2022; 13():950213. PubMed ID: 36072582
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of the prognostic implication and immune infiltration of CISD2 in diffuse large B-cell lymphoma.
Zhang C; Lin Q; Li C; Qiu Y; Chen J; Zhu X
Front Immunol; 2023; 14():1277695. PubMed ID: 38155967
[TBL] [Abstract][Full Text] [Related]
5. High expression of AP2M1 correlates with worse prognosis by regulating immune microenvironment and drug resistance to R-CHOP in diffuse large B cell lymphoma.
Liu X; Zhao X; Yang J; Wang H; Piao Y; Wang L
Eur J Haematol; 2023 Feb; 110(2):198-208. PubMed ID: 36335584
[TBL] [Abstract][Full Text] [Related]
6. Identification and Validation of a DNA Damage Repair-Related Signature for Diffuse Large B-Cell Lymphoma.
Li Y; Liu X; Chang Y; Fan B; Shangguan C; Chen H; Zhang L
Biomed Res Int; 2022; 2022():2645090. PubMed ID: 36281462
[TBL] [Abstract][Full Text] [Related]
7. Low Expression and Promoter Hypermethylation of the Tumour Suppressor SLIT2, are Associated with Adverse Patient Outcomes in Diffuse Large B Cell Lymphoma.
Mohamed G; Talima S; Li L; Wei W; Rudzki Z; Allam RM; Simmons W; Tao Q; Murray PG
Pathol Oncol Res; 2019 Jul; 25(3):1223-1231. PubMed ID: 30739251
[TBL] [Abstract][Full Text] [Related]
8. Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature.
He J; Chen Z; Xue Q; Sun P; Wang Y; Zhu C; Shi W
J Transl Med; 2022 Apr; 20(1):186. PubMed ID: 35468826
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge.
Lavacchi D; Landini I; Perrone G; Roviello G; Mini E; Nobili S
Pharmacol Ther; 2022 Jan; 229():107924. PubMed ID: 34175369
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
Huang H; Fan L; Fu D; Lin Q; Shen J
Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
[TBL] [Abstract][Full Text] [Related]
11. A novel angiogenesis-related scoring model predicts prognosis risk and treatment responsiveness in diffuse large B-cell lymphoma.
Liu Y; Wang J; Shen X; Li L; Zhang N; Wang X; Tang B
Clin Exp Med; 2023 Nov; 23(7):3781-3797. PubMed ID: 37402040
[TBL] [Abstract][Full Text] [Related]
12. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K
BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453
[TBL] [Abstract][Full Text] [Related]
13. Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma.
Chen W; Liang W; He Y; Liu C; Chen H; Lv P; Yao Y; Zhou H
Med Oncol; 2022 Jan; 39(4):44. PubMed ID: 35092504
[TBL] [Abstract][Full Text] [Related]
14. A glycolysis-related gene signatures in diffuse large B-Cell lymphoma predicts prognosis and tumor immune microenvironment.
Cui Y; Leng C
Front Cell Dev Biol; 2023; 11():1070777. PubMed ID: 36755971
[No Abstract] [Full Text] [Related]
15. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
16. A prognostic 15-gene model based on differentially expressed genes among metabolic subtypes in diffuse large B-cell lymphoma.
Hou J; Guo P; Lu Y; Jin X; Liang K; Zhao N; Xue S; Zhou C; Wang G; Zhu X; Hong H; Chen Y; Lu H; Wang W; Xu C; Han Y; Cai S; Liu Y
Pathol Oncol Res; 2023; 29():1610819. PubMed ID: 36816541
[TBL] [Abstract][Full Text] [Related]
17. Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma.
Voropaeva EN; Pospelova TI; Voevoda MI; Maksimov VN; Orlov YL; Seregina OB
BMC Med Genomics; 2019 Mar; 12(Suppl 2):35. PubMed ID: 30871527
[TBL] [Abstract][Full Text] [Related]
18. c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma.
Bouroumeau A; Bussot L; Bonnefoix T; Fournier C; Chapusot C; Casasnovas O; Martin L; McLeer A; Col E; David-Boudet L; Lefebvre C; Algrin C; Raskovalova T; Jacob MC; Vettier C; Chevalier S; Callanan MB; Gressin R; Emadali A; Sartelet H
J Pathol Clin Res; 2021 Nov; 7(6):604-615. PubMed ID: 34374220
[TBL] [Abstract][Full Text] [Related]
19. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
[TBL] [Abstract][Full Text] [Related]
20. How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma.
Falduto A; Cimino F; Speciale A; Musolino C; Gangemi S; Saija A; Allegra A
Blood Rev; 2017 Jul; 31(4):235-249. PubMed ID: 28262268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]